Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.

J Immunother Cancer · 2019 · PMC6683488 · PMID 31383005

Europe PMC DOI

hedged sentence

0.1440

closest p · 2.9× alpha

0.1440

boldest claim

The sentences

showed a trendp = 0.144not close (p > 0.1)

Patients with any positive autoimmune antibody (anti-SOX2, anti-Hu, anti-Yo, anti-VGCCA, anti-VGPCA, anti-nuclear, anti-neutrophil cytoplasmic antibodies) showed a trend for a prolonged survival (18.5 versus 17 months, p = 0.144), a significantly longer median progression free survival (8.8 versus 7.3 months, p = 0.036) and a trend for a higher response rate ( p = 0.066) [ 85 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.